Selecta Biosciences, Inc. (SELB) News
Filter SELB News Items
SELB News Results
|Loading, please wait...|
SELB News Highlights
- For SELB, its 30 day story count is now at 4.
- Over the past 1 day, the trend for SELB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- AVDL, GENE and DNA are the most mentioned tickers in articles about SELB.
Latest SELB News From Around the Web
Below are the latest news stories about Selecta Biosciences Inc that investors may wish to consider to help them evaluate SELB as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Selecta Biosciences (SELB)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report) and Selecta Biosciences (SELB – Research Report) with bullish sentiments. Avadel Pharmaceuticals (AVDL) Needham analyst Ami Fadia maintained a Buy rating on Avadel Pharmaceuticals today and set a price target of $15.00. The company's shares closed last Monday at $6.92, close to its 52-week low of $6.29. According to TipRanks.
Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.
Selecta Biosciences Inc. has chosen Ginkgo Bioworks Holdings Inc. to develop new viral capsids for gene therapies.
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids. This partnership leverages the unique platforms of both companies as they seek to develop next-g
No summary available.
WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available on-demand through the H.C. Wainwright conferen
WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will participate in a panel and one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. Details on the panel can be found below.
Selecta Biosciences Inc. (NASDAQ:SELB) concluded the trading at $3.33 on Wednesday, December 22 with a rise of 0.30% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.32 and 5Y monthly beta was reading 0.98 with its price kept floating in the Selecta Biosciences Inc. (SELB): Worth A Little Bit At $3.33 Read More »
Selecta Biosciences, Inc. (NASDAQ:SELB) Director Timothy A. Springer purchased 211,190 shares of Selecta Biosciences stock in a transaction dated Wednesday, December 15th. The stock was bought at an average cost of $2.99 per share, with a total value of $631,458.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which 
Selecta Biosciences, Inc. (NASDAQ:SELB) CEO Carsten Brunn sold 17,196 shares of the stock in a transaction that occurred on Friday, December 10th. The shares were sold at an average price of $2.99, for a total transaction of $51,416.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this […]